The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development

Drug delivery is an integral part of the drug development process, influencing safety and efficacy of active pharmaceutical ingredients. The application of nanotechnology has enabled the discovery of novel formulations for numerous therapeutic purposes across multiple disease areas. However, evaluation of novel formulations in clinical scenarios is slow and hampered due to various ethical and logistical barriers. Computational models have the ability to integrate existing domain knowledge and mathematical correlations, to rationalize the feasibility of using novel formulations for safely enhancing drug delivery, identifying suitable candidates, and reducing the burden on preclinical and clinical studies. In this review, types of novel formulations and their application through several routes of administration and the use of modeling approaches that can find application in different stages of the novel formulation development process are discussed.

[1]  D. Bouard,et al.  Viral vectors: from virology to transgene expression , 2009, British journal of pharmacology.

[2]  Jim E Riviere,et al.  A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice , 2015, Nanotoxicology.

[3]  G. Calin,et al.  Progresses towards safe and efficient gene therapy vectors , 2015, Oncotarget.

[4]  T. Ishida,et al.  Liposomal Delivery Systems: Design Optimization and Current Applications. , 2017, Biological & pharmaceutical bulletin.

[5]  P. Møller,et al.  Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape , 2018, International journal of nanomedicine.

[6]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[7]  Ninad Varkhede,et al.  Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model. , 2018, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[8]  P. Annaert,et al.  Modeling the Time Course of the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate Nano-/Microcrystals and Polystyrene Microspheres in the Rat , 2016, Toxicologic pathology.

[9]  Samir Mitragotri,et al.  Nanoparticles in the clinic: An update , 2019, Bioengineering & translational medicine.

[10]  Nouri Nayerossadat,et al.  Viral and nonviral delivery systems for gene delivery , 2012, Advanced biomedical research.

[11]  Jin Yong Lee,et al.  Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009–2016: A nationwide study , 2018, Scientific Reports.

[12]  Vincent Jannin,et al.  Solid lipid excipients - matrix agents for sustained drug delivery. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Madhukar Pai,et al.  Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities , 2018, BMJ Global Health.

[14]  K. Shailubhai,et al.  Immunotherapy with oral administration of humanized anti‐CD3 monoclonal antibody: a novel gut‐immune system‐based therapy for metaflammation and NASH , 2018, Clinical and experimental immunology.

[15]  A. Owen,et al.  Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. , 2019, The Journal of antimicrobial chemotherapy.

[16]  Ji-Ho Park,et al.  Liposomal delivery systems for intestinal lymphatic drug transport , 2016, Biomaterials Research.

[17]  M. Jamei,et al.  A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins , 2015, The AAPS Journal.

[18]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[19]  Xiaohui Chen,et al.  Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes , 2016, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  Yin Zhang,et al.  A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice , 2018, BMC Systems Biology.

[21]  A. Chauhan,et al.  A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. , 2010, Journal of pharmaceutical sciences.

[22]  Andrew Owen,et al.  Special issue of BJP on Nanomedicine , 2014, British journal of pharmacology.

[23]  Graham M. Dykes,et al.  Dendrimers: a review of their appeal and applications , 2001 .

[24]  D. Simberg,et al.  The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[25]  Louis A. Pagliaro,et al.  Naltrexone , 2020, Reactions Weekly.

[26]  C. Flexner,et al.  Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  Yahya E Choonara,et al.  A prospective overview of the essential requirements in molecular modeling for nanomedicine design. , 2013, Future Medicinal Chemistry.

[28]  C. V. van Halsema,et al.  Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential , 2019, HIV/AIDS.

[29]  Varun Jaiswal,et al.  Quantitative structure–activity relationship (QSAR) studies as strategic approach in drug discovery , 2014, Medicinal Chemistry Research.

[30]  A. Ostör,et al.  The long road of biopharmaceutical drug development: from inception to marketing. , 2010, QJM : monthly journal of the Association of Physicians.

[31]  B. Bannwarth,et al.  Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer? , 2017, Drugs.

[32]  Amin Rostami‐Hodjegan,et al.  Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence , 2017, Clinical pharmacology and therapeutics.

[33]  Byung Kook Lee,et al.  Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[34]  C. L. Ventola,et al.  The nanomedicine revolution: part 1: emerging concepts. , 2012, P & T : a peer-reviewed journal for formulary management.

[35]  Robert Langer,et al.  Reservoir-based drug delivery systems utilizing microtechnology. , 2012, Advanced drug delivery reviews.

[36]  Theresa M Allen,et al.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.

[37]  Danuta Leszczynska,et al.  Chapter 10:Nano-QSAR: Advances and Challenges , 2012 .

[38]  L. Citrome,et al.  Aripiprazole Lauroxil , 2017, Journal of clinical psychopharmacology.

[39]  Tejraj M Aminabhavi,et al.  Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[40]  Alanod D AlQahtani,et al.  Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  B. Ruozi,et al.  Protein corona and nanoparticles: how can we investigate on? , 2017, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[42]  T. Shapiro,et al.  Long-acting injectable atovaquone nanomedicines for malaria prophylaxis , 2018, Nature Communications.

[43]  Jim E Riviere,et al.  Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. , 2009, Nano letters.

[44]  Grover,et al.  Quantitative structure-property relationships in pharmaceutical research - Part 2. , 2000, Pharmaceutical science & technology today.

[45]  C. Flexner,et al.  In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents , 2018, Clinical Pharmacokinetics.

[46]  Meng Chen,et al.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection , 2015, Patient preference and adherence.

[47]  G. De Sarro,et al.  Pharmacokinetic drug-drug interaction and their implication in clinical management , 2013, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[48]  M. Newman,et al.  Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs , 1999, Human & experimental toxicology.

[49]  J. Qi,et al.  An imaging-driven model for liposomal stability and circulation. , 2010, Molecular pharmaceutics.

[50]  Baojian Wu,et al.  Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112 , 2015, International journal of nanomedicine.

[51]  Aravind Subramanian,et al.  Perturbational profiling of nanomaterial biologic activity , 2008, Proceedings of the National Academy of Sciences.

[52]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[53]  Siglas de Palabras I.L.A. , 2016 .

[54]  Gina M. Prescott,et al.  Long‐Acting Reversible Contraception: A Review in Special Populations , 2014, Pharmacotherapy.

[55]  Raymond Laflamme,et al.  A review of applications of principles of quantum physics in oncology: do quantum physics principles have any role in oncology research and applications? , 2019, Journal of Radiotherapy in Practice.

[56]  M. O'Connor,et al.  Identification of active signaling pathways by integrating gene expression and protein interaction data , 2018, BMC Systems Biology.

[57]  Natalie von Goetz,et al.  Translocation of gold nanoparticles across the lung epithelial tissue barrier: Combining in vitro and in silico methods to substitute in vivo experiments , 2015, Particle and Fibre Toxicology.

[58]  A. Duschl Chapter 12 – Nanomedicine , 2016 .

[59]  C. Flexner,et al.  Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling , 2019, The Journal of infectious diseases.

[60]  C. Flexner,et al.  Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[61]  Mark R. Prausnitz,et al.  Rapidly separable microneedle patch for the sustained release of a contraceptive , 2019, Nature Biomedical Engineering.

[62]  M. Baliki,et al.  Chronic pain: the role of learning and brain plasticity. , 2014, Restorative neurology and neuroscience.

[63]  A. Mitra,et al.  Long-term delivery of protein therapeutics , 2015, Expert opinion on drug delivery.

[64]  Andrew Worth,et al.  Applying quantitative structure-activity relationship approaches to nanotoxicology: current status and future potential. , 2013, Toxicology.

[65]  D. Podzamczer,et al.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial , 2017, The Lancet.

[66]  Tiziano Tuccinardi,et al.  The History of Nanoscience and Nanotechnology: From Chemical–Physical Applications to Nanomedicine , 2019, Molecules.

[67]  Ryan F. Donnelly,et al.  Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[68]  D. Mager,et al.  Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition , 2013, Pharmaceutical Research.

[69]  Carlo Montemagno,et al.  An Overview of Molecular Modeling for Drug Discovery with Specific Illustrative Examples of Applications , 2019, Molecules.

[70]  Tomasz Puzyn,et al.  Nano-quantitative structure-activity relationship modeling using easily computable and interpretable descriptors for uptake of magnetofluorescent engineered nanoparticles in pancreatic cancer cells. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.

[71]  C. Yeh,et al.  Macrophages as Drug Delivery Carriers for Acoustic Phase-Change Droplets. , 2018, Ultrasound in medicine & biology.

[72]  Kostas Kostarelos,et al.  Physiologically based pharmacokinetic modeling of nanoparticles. , 2010, ACS nano.

[73]  Zuben E. Sauna,et al.  Recent advances in (therapeutic protein) drug development , 2017, F1000Research.

[74]  C. Free,et al.  A systematic review and meta-analysis in the effectiveness of mobile phone interventions used to improve adherence to antiretroviral therapy in HIV infection , 2019, BMC Public Health.

[75]  Sara Soares,et al.  Nanomedicine: Principles, Properties, and Regulatory Issues , 2018, Front. Chem..

[76]  Gang Bao,et al.  The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. , 2016, Nanomedicine.

[77]  Marco Siccardi,et al.  Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV , 2015, Clinical Pharmacokinetics.

[78]  Ventola Cl,et al.  The nanomedicine revolution: part 1: emerging concepts. , 2012, P & T : a peer-reviewed journal for formulary management.

[79]  Bin Li,et al.  Applications of machine learning in drug discovery and development , 2019, Nature Reviews Drug Discovery.

[80]  H. Gendelman,et al.  Cell-mediated drug delivery , 2011, Expert opinion on drug delivery.

[81]  Ming-Hsien Tsai,et al.  Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. , 2008, Environmental science & technology.

[82]  Yanan Cui,et al.  Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system , 2017, Drug development and industrial pharmacy.

[83]  Y. Barenholz,et al.  Annals of the New York Academy of Sciences Nanomedicines: Addressing the Scientific and Regulatory Gap , 2022 .

[84]  Cristina Maderuelo,et al.  Critical factors in the release of drugs from sustained release hydrophilic matrices. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[85]  K. Hungerbuhler,et al.  Using physiologically based pharmacokinetic (PBPK) modeling for dietary risk assessment of titanium dioxide (TiO2) nanoparticles , 2015, Nanotoxicology.

[86]  T. Xia,et al.  Development of structure-activity relationship for metal oxide nanoparticles. , 2013, Nanoscale.

[87]  Projit Bihari Mukharji Injection , 2017 .

[88]  I. Ivanov,et al.  Comparative Study of Predictive Computational Models for Nanoparticle‐Induced Cytotoxicity , 2010, Risk analysis : an official publication of the Society for Risk Analysis.

[89]  Vittorio Cristini,et al.  Mathematical modeling in cancer nanomedicine: a review , 2019, Biomedical Microdevices.

[90]  S. Rovesti,et al.  Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting , 2019, Neuropsychiatric disease and treatment.

[91]  M. Thew Etonogestrel Implant—To Leave or Stay: A Case Series , 2017, Global Pediatric Health.

[92]  Liang Zhao,et al.  The Antibody Drug Absorption Following Subcutaneous or Intramuscular Administration and Its Mathematical Description by Coupling Physiologically Based Absorption Process with the Conventional Compartment Pharmacokinetic Model , 2013, Journal of clinical pharmacology.

[93]  Julio C. Facelli,et al.  A review of the applications of data mining and machine learning for the prediction of biomedical properties of nanoparticles , 2016, Comput. Methods Programs Biomed..

[94]  R. Banerjee,et al.  Liposomes: Applications in Medicine , 2001, Journal of biomaterials applications.

[95]  Olivier Jolliet,et al.  Physiologically based pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticles in rats , 2014, Nanotoxicology.

[96]  D. Hazuda,et al.  Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[97]  T. S. Harrison,et al.  Vincristine Sulfate Liposome Injection , 2013, BioDrugs.

[98]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[99]  Min Li,et al.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles , 2016, The AAPS Journal.

[100]  W. Wolfgang Fleischhacker,et al.  The Use of Long-Acting Injectable Antipsychotics in Schizophrenia , 2017, Current Treatment Options in Psychiatry.

[101]  A. Stein,et al.  Benchmarking QSP Models Against Simple Models: A Path to Improved Comprehension and Predictive Performance , 2018, CPT: pharmacometrics & systems pharmacology.

[102]  L. Sweeney,et al.  Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats. , 2015, Regulatory toxicology and pharmacology : RTP.

[103]  Can Zhang,et al.  Cell-based drug delivery systems for biomedical applications , 2018, Nano Research.

[104]  R. N. Brogden,et al.  Dantrolene Sodium , 2020, Drugs.

[105]  David Taylor,et al.  Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics , 2019, Therapeutic advances in psychopharmacology.

[106]  Olivier Jolliet,et al.  Tissue distribution and pharmacokinetics of stable polyacrylamide nanoparticles following intravenous injection in the rat. , 2011, Toxicology and applied pharmacology.

[107]  Vladimir Lobaskin,et al.  Coarse-grained model of adsorption of blood plasma proteins onto nanoparticles. , 2015, The Journal of chemical physics.

[108]  Hao Hu,et al.  A Comprehensive Map of FDA-Approved Pharmaceutical Products , 2018, Pharmaceutics.

[109]  徐积恩 Granisetron , 1991, Reactions Weekly.

[110]  Daniel Kaschek,et al.  Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development , 2019, CPT: pharmacometrics & systems pharmacology.

[111]  R. Upton,et al.  Food, gastrointestinal pH, and models of oral drug absorption , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[112]  I. Doytchinova,et al.  Quantitative Structure - Pharmacokinetics Relationships Analysis of Basic Drugs: Volume of Distribution. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[113]  T. Abribat,et al.  The rise and rise of drug delivery , 2005, Nature Reviews Drug Discovery.

[114]  V. Krishnan,et al.  Physiologically Based Pharmacokinetic Modeling of Fluorescently Labeled Block Copolymer Nanoparticles for Controlled Drug Delivery in Leukemia Therapy , 2015, CPT: pharmacometrics & systems pharmacology.

[115]  P. Aubourg,et al.  Hematopoietic Stem Cell Transplantation and Hematopoietic Stem Cell Gene Therapy in X‐Linked Adrenoleukodystrophy , 2009, Brain pathology.

[116]  David Taylor,et al.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal , 2014, Therapeutic advances in psychopharmacology.

[117]  V. Mishra,et al.  Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems , 2018, Pharmaceutics.

[118]  Andrew P. Worth,et al.  QSAR modeling of nanomaterials. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[119]  Hyo-Jick Choi,et al.  Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals , 2019, Pharmaceutics.

[120]  P. Hoet,et al.  Interactions of nanomaterials with the immune system. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[121]  V. Stevens,et al.  Predicting poor adherence to antiretroviral therapy among treatment-naïve veterans infected with human immunodeficiency virus , 2018, Medicine.

[122]  H. Noteborn,et al.  Drug delivery systems. , 1989, Current opinion in oncology.

[123]  S. Mitragotri,et al.  Nanocrystals: A perspective on translational research and clinical studies , 2018, Bioengineering & translational medicine.

[124]  Jerzy Leszczynski,et al.  Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles. , 2011, Nature nanotechnology.

[125]  K. Avgoustakis,et al.  Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content , 2012, International journal of nanomedicine.

[126]  Darren Michael Moss,et al.  Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling , 2014, British journal of pharmacology.

[127]  A. Tropsha,et al.  Quantitative nanostructure-activity relationship modeling. , 2010, ACS nano.

[128]  R. Weissleder,et al.  Cell-specific targeting of nanoparticles by multivalent attachment of small molecules , 2005, Nature Biotechnology.

[129]  C. Wu,et al.  Delivery systems for gene therapy , 1991, Biotherapy.

[130]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[131]  S. Balu-Iyer,et al.  Delivery of therapeutic proteins. , 2010, Journal of pharmaceutical sciences.

[132]  S. Talegaonkar,et al.  Nanocrystalization: An Emerging Technology to Enhance the 
Bioavailability of Poorly Soluble Drugs , 2019, Pharmaceutical nanotechnology.

[133]  R. Wallerstein,et al.  THE TREATMENT OF IRON-DEFICIENCY ANEMIA WITH INTRAVENOUS IRON DEXTRAN. , 1964, Blood.

[134]  A. Molinari,et al.  Liposomes as nanomedical devices , 2015, International journal of nanomedicine.

[135]  Kit-Kay Mak,et al.  Artificial intelligence in drug development: present status and future prospects. , 2019, Drug discovery today.

[136]  A. Kaushik,et al.  Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection , 2019, Antimicrobial Agents and Chemotherapy.

[137]  A. D. V. van Staden,et al.  Harnessing Macrophages for Controlled-Release Drug Delivery: Lessons From Microbes , 2019, Front. Pharmacol..

[138]  Samir Mitragotri,et al.  Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.

[139]  J. Au,et al.  Target Site Delivery and Residence of Nanomedicines: Application of Quantitative Systems Pharmacology , 2019, Pharmacological Reviews.

[140]  James S. Peerless,et al.  Advances in Molecular Modeling of Nanoparticle-Nucleic Acid Interfaces. , 2017, Bioconjugate chemistry.

[141]  I. Brosens,et al.  Long-Acting Hormonal Contraception , 2015, Women's health.

[142]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[143]  J. Gallant,et al.  Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. , 2017, The lancet. HIV.

[144]  M. Swierczewska,et al.  What is the future of PEGylated therapies? , 2015, Expert opinion on emerging drugs.

[145]  H. Harashima,et al.  Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[146]  J. Burke,et al.  Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1 , 2018, CPT: pharmacometrics & systems pharmacology.

[147]  T. Koh,et al.  Macrophage‐based therapeutic strategies in regenerative medicine , 2017, Advanced drug delivery reviews.

[148]  Huile Gao,et al.  The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior , 2014, Expert opinion on drug delivery.

[149]  E. Fry BUPRENORPHINE , 1980, The Lancet.

[150]  G. Hortelano,et al.  Sustained expression of coagulation factor IX by modified cord blood‐derived mesenchymal stromal cells , 2014, The journal of gene medicine.

[151]  S. Wilhelm,et al.  Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. , 2019, Advanced drug delivery reviews.

[152]  Kshirsagar Drug delivery systems , 2000 .

[153]  A. Azagew,et al.  Non-adherence to anti-tuberculosis treatment, reasons and associated factors among TB patients attending at Gondar town health centers, Northwest Ethiopia , 2018, BMC Research Notes.

[154]  Jerzy Leszczynski,et al.  QSAR as a random event: modeling of nanoparticles uptake in PaCa2 cancer cells. , 2013, Chemosphere.